Drug Profile
ADX 104
Alternative Names: ADX-104Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Aldeyra Therapeutics
- Class Anti-inflammatories; Eye disorder therapies; Skin disorder therapies
- Mechanism of Action Aldehyde inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inborn error metabolic disorders; Sjogren-Larsson syndrome
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Inborn-error-metabolic-disorders in USA (Parenteral)
- 28 Apr 2021 No recent reports of development identified for preclinical development in Sjogren-Larsson syndrome in USA (Parenteral)
- 02 Jun 2017 Aldeyra Therapeutics has patent protection and pending patent applications for ADX 104 (Aldeyra Therapeutics Form 10-K, March 2017)